Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 9/20 | 0.69 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.58 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.58 |
| ▸ | FBP1 | P09467 | 1/20 | 0.58 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 8/20 | 0.53 |
| ▸ | KDR | P35968 | 7/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568019 | 0.87 | ABCG2 (0.80) | ABCG2ABCB1FBP1EGFR | |
| SCHEMBL13234665 | 0.87 | EGFR (0.70) | ABCG2ABCB1ABCC1SLC2A1EGFR | |
| SCHEMBL2257647 | 0.85 | ABCG2 (0.74) | ABCG2ABCB1ABCC1 | |
| SCHEMBL5473767 | 0.82 | ABCG2 (1.00) | ABCG2EGFRKDR | |
| Hydrochloric Acid SCHEMBL5478012 | 0.81 | ABCG2 (0.98) | ABCG2EGFRKDR | |
| SCHEMBL12069892 | 0.81 | FBP1 (0.74) | ABCG2FBP1SLC2A1EGFRKDR | |
| SCHEMBL2257566 | 0.78 | ABCG2 (0.71) | ABCG2EGFR | |
| SCHEMBL372022 | 0.77 | KDR (0.50) | ABCG2KDR | |
| Hydrochloric Acid SCHEMBL8934067 | 0.76 | EGFR (0.67) | ABCG2FBP1SLC2A1EGFRKDR | |
| Hydrochloric Acid SCHEMBL8809094 | 0.75 | FBP1 (0.60) | ABCG2FBP1SLC2A1EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | ABCG2 311/4885ABCB1 179/4885ABCC1 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.